Eton Pharmaceuticals Q2 EPS Crushes Estimates, Raises 2026 Revenue Guidance to Over $145M
ETON has more than doubled off its 52-week low of $14.27.
Summary
Eton Pharmaceuticals delivered a blowout Q2, with adjusted EPS of $0.43 versus the $0.11 consensus and revenue up 99% year-over-year, driven by the HEMANGEOL relaunch and faster-than-expected patient conversion. Management raised full-year 2026 revenue guidance to over $145 million from over $120 million, lifted adjusted EBITDA margin expectations to at least 35% from 30%, and now sees adjusted gross margin above 70%. Shares jumped about 24% in extended trading, pushing the stock above its 52-week high. This follows the recent licensing of ASN-001 for infantile hemangiomas, adding another growth driver. The magnitude of the beat and guidance raise is material for a company of this size, and the stock's move reflects a significant re-rating.
At the time of this announcement, ETON was trading at $51.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.1B. The 52-week trading range was $14.27 to $50.18. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Reuters.